|
Video: What is a Stock Split?
|
|
Catalyst Biosciences, together with its subsidiary, is a biopharmaceutical company focused on development and commercialization of Hydronidone for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease) in the U.S. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the U.S. and generated pharmacokinetic, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. According to our CBIO split history records, CBIO has had 3 splits. | |
|
CBIO (CBIO) has 3 splits in our CBIO split history database. The first split for CBIO took place on August 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split. CBIO's second split took place on February 13, 2017. This was a 1 for 15 reverse split, meaning for each 15 shares of CBIO owned pre-split, the shareholder now owned 1 share. For example, a 142.857142857143 share position pre-split, became a 9.52380952380952 share position following the split. CBIO's third split took place on September 21, 2022.
When a company such as CBIO conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CBIO split history from start to finish, an original position size of 1000 shares would have turned into 9.52380952380952 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CBIO shares, starting with a $10,000 purchase of CBIO, presented on a split-history-adjusted basis factoring in the complete CBIO split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
10/30/2023 |
|
Start price/share: |
$445.20 |
|
End price/share: |
$0.51 |
|
Starting shares: |
22.46 |
|
Ending shares: |
265.56 |
|
Dividends reinvested/share: |
$61.41 |
|
Total return: |
-98.65% |
|
Average Annual Total Return: |
-36.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$135.54 |
|
Years: |
9.52 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
10/30/2023 |
|
Start price/share: |
$445.20 |
|
End price/share: |
$0.51 |
|
Dividends collected/share: |
$61.41 |
|
Total return: |
-86.09% |
|
Average Annual Total Return: |
-18.71% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,391.57 |
|
Years: |
9.52 |
|
|
|
Date |
Ratio |
08/21/2015 | 1 for 7 | 02/13/2017 | 1 for 15 | 09/21/2022 | 1 for 1 |
|
|